Helping women make sound decisions regarding discontinuation of systemic menopausal
hormone therapy (MHT) represents a challenge for clinicians. The goal of striving
for the lowest dose of MHT for the shortest amount of time would seem disconnected
from the reality that many women experience vasomotor symptoms (VMS) for a decade
or more [
1
,
2
]. Thus, determining why, when and how to discontinue the use of MHT represent important
clinical considerations.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Extended duration use of menopausal hormone therapy.Menopause. 2014; 21: 679-681
- Management of menopausal symptoms.Obstet. Gynecol. 2015; 126: 859-876
- Practice bulletin No. 141: management of menopausal symptoms.Obstet. Gynecol. 2014; 123: 202-216
- NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older.Menopause. 2015; 22: 685-686
- The 2012 hormone therapy position statement of The North American Menopause Society.Menopause. 2012; 19: 257-271
Article info
Publication history
Published online: March 24, 2016
Accepted:
March 22,
2016
Received:
March 15,
2016
Identification
Copyright
© 2016 Elsevier Ireland Ltd. All rights reserved.
